Evidence map›Paper›PMID 34405118›Full record

ArticleWellcome open research2021

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.

Graham S Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 1 country.

Graham S CookeDepartment of Infectious Disease, Imperial College London, London, W2 1NY, UK.ORCID https://orcid.org/0000-0001-6475-5056
Sarah PettMRC Clinical Trials Unit, University College London Medical School, London, UK.
Leanne McCabeMRC Clinical Trials Unit, University College London Medical School, London, UK.ORCID https://orcid.org/0000-0002-6509-8999
Chris JonesDepartment of Infectious Disease, Imperial College London, London, W2 1NY, UK.ORCID https://orcid.org/0000-0002-6301-2282
Richard GilsonMortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK.
Sumita VermaHepatology, Brighton and Sussex Medical School, Brighton, UK.
Stephen D RyderHepatology, Nottingham University Hospitals NHS Trust, Nottingham, UK.ORCID https://orcid.org/0000-0001-9649-4444
Jane D CollierHepatology, John Radcliffe Hospital, Oxford, UK.
Stephen T BarclayGastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
Aftab AlaClinical and Experimental Medicine, University of Surrey, Guilford, UK.
Sanjay BhaganiInfectious Diseases, Royal Free Hampstead NHS Trust Hospital, London, UK.ORCID https://orcid.org/0000-0003-2557-4337
Mark NelsonHIV Medicine, Chelsea & Westminster NHS Trust, London, UK.
Chinlye Ch'NgSwansea Bay University Health Board, Swansea, UK.
Ben StoneInfectious Diseases, Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, UK.
Martin WiselkaInfectious Diseases, University Hospitals of Leicester NHS Trust, Leicester, UK.ORCID https://orcid.org/0000-0002-4587-5826
Daniel FortonHepatology, St George's Hospital, London, London, UK.
Stuart McPhersonHeaptology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle, UK.ORCID https://orcid.org/0000-0002-5638-2453
Rachel HalfordHepatitis C Trust, London, UK.
Dung NguyenPeter Medawar Buildling for Pathogen Research, Oxford, UK.ORCID https://orcid.org/0000-0001-9390-9990
David SmithPeter Medawar Buildling for Pathogen Research, Oxford, UK.ORCID https://orcid.org/0000-0001-7778-7137
Azim AnsariPeter Medawar Buildling for Pathogen Research, Oxford, UK.
Emily DennisMRC Clinical Trials Unit, University College London Medical School, London, UK.
Fleur HudsonMRC Clinical Trials Unit, University College London Medical School, London, UK.
Eleanor J BarnesPeter Medawar Buildling for Pathogen Research, Oxford, UK.
Ann Sarah WalkerMRC Clinical Trials Unit, University College London Medical School, London, UK.
MRC Clinical Trials Unit at UCL · GBMedawar Building for Pathogen Research · GBCentral and North West London NHS Foundation Trust · GBJohn Radcliffe Hospital · GBNIHR Imperial Biomedical Research Centre · GBBrighton and Sussex Medical School · GBChelsea and Westminster Hospital NHS Foundation Trust · GBGlasgow Royal Infirmary · GBNewcastle upon Tyne Hospital · GBNottingham University Hospitals NHS Trust · GBRoyal Free London NHS Foundation Trust · GBSheffield Teaching Hospitals NHS Foundation Trust · GBSt George's Hospital · GBSwansea Bay University Health Board · GBThe Hepatitis C Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity of Surrey · GB

Funding

Department of Health 14/02/17Medical Research Council MC_UU_12023/22Medical Research Council MR/K01532X/1Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialhepatitisribavirinshort coursetreatment

Identifiers

PMID34405118
PMCPMC8361811
OpenAlexW3121794507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.